Viral pneumonia in a patient treated with pembrolizumab – similarity with immune-related pneumonitis

Czech version

Authors: J. Podhorec ¹; L. Jakubíková ²; O. Bílek ¹; I. Kiss ¹; A. Poprach ¹
Authors‘ workplace: Klinika komplexní onkologické péče LF MU a MOÚ Brno ¹; Klinika nemocí plicních a tuberkulózy LF MU a FN Brno ²
Published in: Klin Onkol 2024; 38(5): 380-383
Category: Case Reports
doi: https://doi.org/10.48095/ccko2024380

Overview

Background: Immunotherapy is one of the fundamental treatment modalities, especially in the treatment of metastatic non-small cell lung carcinoma, but it is also applied in neoadjuvant, or adjuvant therapy. A certain limitation continues to be immune-mediated toxicity and the broad clinical spectrum of its manifestations, which can present considerable differential diagnostic challenges. Case: We present a case of a female patient who has been treated at our institute since February 2023 for metastatic squamous cell carcinoma of the right lung with first-line systemic therapy of pembrolizumab in initial combination with carboplatin and paclitaxel. Reassessment after four cycles of treatment showed a significant regression of the oncological finding, but also partial fibrotic changes in both lungs. The patient was completely asymptomatic and after consultation with her, it was decided to continue the treatment, now with pembrolizumab monotherapy. Several days after administration, the patient developed resting dyspnea, cough, and fevers. She consulted this deterioration of her condition only at the next scheduled appointment. Persistent dyspnea raised suspicion of immune-mediated pneumonitis. CT of the chest showed significant involvement of all lung lobes and treatment with corticosteroids and antibiotics was initiated. Through bronchoalveolar lavage, positivity for rhinovirus and enterovirus was detected. Viral pneumonia was assessed as the most likely cause of the clinical finding. The established corticosteroid treatment was gradually reduced and after discussion with the patient, we continued the administration of pembrolizumab. A follow-up CT of the lungs showed both further significant regression of the tumor and significant regression of inflammatory changes. Currently, the patient is after a total of 14 cycles of chemo/immunotherapy (of which 9 cycles of pembrolizumab after re-initiation), clinically in excellent condition, while a significant therapeutic response continues. Conclusion: Our case report emphasizes the need for a broader differential diagnosis in the event of pulmonary complications during the administration of immunotherapy. Correct diagnosis of these complications can, among other things, fundamentally affect oncological treatment.

Keywords:

checkpoint inhibitors – non-small cell lung carcinoma – pembrolizumab – drug side effects – pneumonitis

Sources

1. Schneider BJ, Naidoo J, Santomasso BD et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol 2021; 39 (36): 4073–4126. doi: 10.1200/JCO.21.01440.

2. Yin J, Wu Y, Yang X et al. Checkpoint inhibitor pneumonitis induced by anti-PD-1/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism. Front Immunol 2022; 13: 830631. doi: 10.3389/fimmu.2022.830631.

3. Cook S, Samuel V, Meyers DE et al. Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Netw Open 2024; 7 (1): e2352302. doi: 10.1001/jamanetworkopen.2023.52302.

4. Disayabutr S, Calfee CS, Collard HR et al. Interstitial lung diseases in the hospitalized patient. BMC Medicine 2015; 13 (1): 245. doi: 10.1186/s12916-015-0487-0.

5. Nishino M, Giobbie-Hurder A, Hatabu H et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016; 2 (12): 1607–1616. doi: 10.1001/jamaoncol.2016.2453.

6. Novello S, Kowalski DM, Luft A et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol 2023; 41 (11): 1999–2006. doi: 10.1200/JCO.22.01990.

7. National Comprehensive Cancer Network: Management of immunotherapy-related toxicities. Version 1.2024. [online]. Available from: https: //www.nccn.org/guidelines/guidelines-detail?category=3&id=1486.